Charles River Labs CEVP Shannon M. Parisotto disposes of $302,579 in common shares
Bitget2026/10/08 00:33Shannon M. Parisotto, CEVP, Disc & Safety Assessment at Charles River Laboratories, exercised stock options for 981 shares on Oct. 5, 2026. Sold 981 shares at USD 308.44 on the same day, leaving 4,807 shares held directly. Option exercise price was USD 208.44; 2,944 stock options remained beneficially owned following the transaction. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Charles River Laboratories International Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001952784-26-000003), on October 07, 2026, and is solely responsible for the information contained therein.
- Shannon M. Parisotto, CEVP, Disc & Safety Assessment at Charles River Laboratories, exercised stock options for 981 shares on Oct. 5, 2026.
- Sold 981 shares at USD 308.44 on the same day, leaving 4,807 shares held directly.
- Option exercise price was USD 208.44; 2,944 stock options remained beneficially owned following the transaction.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail
Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

Canaccord Genuity: Lowers Oklo's target price to $66

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.
Dental treatment company vVardis has announced the terms for its $214 million US IPO.
